DDInter458 DDInter1676
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cyclosporine {u} (Compound) treats {v} (Disease) focal segmental glomerulosclerosis
Cyclosporine {u} (Compound) binds {v} (Gene) SLC10A2
Cyclosporine {u} (Compound) upregulates {v} (Gene) IFRD1
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Cyclosporine {u} (Compound) downregulates {v} (Gene) CENPF
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Cyclosporine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPIB
Cyclosporine (Compound) treats focal segmental glomerulosclerosis (Disease)
Cyclosporine (Compound) binds SLC10A2 (Gene)
Cyclosporine (Compound) upregulates IFRD1 (Gene)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Cyclosporine (Compound) downregulates CENPF (Gene)
Cyclosporine (Compound) causes Injury (Side Effect)
Cyclosporine (Compound) binds PPIB (Gene) and Cyclosporine (Compound) upregulates PPIB (Gene)